Emerging Wellness Foods Brand Rritual Mushrooms Inc. is developing plant-based superfood products to lead out a fledgling market segment that has a high degree of promise as consumer interest in functional foods increases
While the mushroom therapeutics subcategory of products is still new and developing, analysts researching the overall functional foods market expect the industry to grow at a CAGR of 7.9 percent to $275.77 billion between 2019 and 2025
Rritual Mushrooms’ introductory product line draws on the reputations of the Chaga, Lion’s Mane and Reishi mushrooms as beneficial to overall wellness, combining them with herbal remedy adaptogens in powdered elixirs
The three formulations are being rolled out this fall in 14-stick packs and in 250-gram tubs, as well as in a 14-day variety pack that includes all three elixirs
Researchers have found “enormous potential” for using mushrooms in functional foods, describing the fungal growth’s immunomodulating, anti-tumor, hypocholesterol and anti-bacterial properties as rife with opportunity for food products such as cereal and bread flours as well as cheeses and cheese-related products (https://nnw.fm/avg7h).
That potential is now being realized with the initial slate of products from lifestyle therapeutics innovator Rritual Mushrooms Inc., whose non-psychoactive wellness elixirs include a Chaga blend designed to augment immunity, a Lion’s Mane blend designed to support cognitive function and brain health, and a Reishi blend to boost the body’s ability to fight anxiety.
Rritual Mushrooms emerged in 2019 as a fledgling company targeting a fledgling industry segment in which no dominant brand has yet emerged to lead the functional foods subcategory. The company is building toward an IPO.
Despite the apparent novelty of the mushroom wellness movement, market analysts at Grand View Research, Inc. stated last year that they expect the overall functional foods market size to reach $275.77 billion in valuation by 2025, expanding at a CAGR of 7.9 percent between 2019 and 2025 (https://nnw.fm/48iA6), and mushroom food products stand to benefit as part of the trend.
The novel coronavirus pandemic that emerged this year is only expected to increase the demand for functional foods and other nutraceuticals as an infection-wary public seeks to utilize more immunity-boosting supplements in their diets.
In June, Rritual Mushrooms introduced Dr. Mike Hart as the company’s president who will help guide Rritual through plant-based wellness therapy developments (https://nnw.fm/38YgR). Hart operates his own family medicine clinic in London, Ontario, where he became the first physician in the locality to open a cannabis clinic in 2014. He continues to use wellness therapies to treat patients’ symptoms such as pain, inflammation, insomnia and depression.
“My belief is that mental fitness is a daily ritual, and Rritual’s product portfolio and approach completely supports my current research and values as a seasoned, plant-based practitioner,” Hart stated in the announcement of his appointment.
In general, mushrooms have twice the protein of asparagus, cabbage and other vegetables, and 12 times the protein found in oranges and apples. Edible mushroom are a good source of several vitamins, including thiamine (“B1”), riboflavin (“B2”), niacin, biotin and ascorbic acid (“C”) (https://nnw.fm/8oheF).
Rritual Mushroom’s product line pairs the Chaga mushroom with the adaptogen Eleuthero root, Lion’s Mane mushroom with the adaptogen Rhodiola root and the Reishi mushroom with the adaptogen Ashwagandha root for products full of bioactive polysaccharides that are helpful to the biome (https://nnw.fm/LFawP). Adaptogens are natural substances used in herbal remedies because they are thought to increase the resistance of organisms to biological stresses (https://nnw.fm/I3nTL).
The three formulations will be available in 14-stick packs and in 300-gram tubs during the fall, as well as a 14-day variety pack that includes all three elixirs. They will be marketed through Rritual’s website and the company’s Amazon store initially before expanding to other online and brick-and-mortar outlets.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
“Mental Fitness is a Daily Ritual“
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Wednesday, October 21st, 2020UncategorizedComments Off on Mushrooms’ Potential in Functional Foods Market Being Realized by Therapeutics Innovator Rritual Mushrooms
180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork(“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and the companies that are developing those drugs. 180 Life Sciences is one of those companies. 180 Life Sciences Corp. was founded by four scientists that have a successful track record of developing new therapeutics that were acquired by larger pharmaceutical companies, sometimes for billions of dollars. The group of renowned scientist-entrepreneurs is focusing on replicating their past success with a pipeline of drug candidates in sequential stages of development that target untapped markets with significant potential.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. KBL Merger Corp. IV previously announced plans to merge with 180 Life Sciences and, in connection with the merger, consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on Aug. 28, 2020. Close of the business combination is expected in the fourth quarter of 2020. Following the merger, the new company will be listed on the Nasdaq Capital Market under ticker symbol “ATNF.” For more information, visit the company’s website at www.180LifeSciences.com.
KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap, with each share of 180 Life Sciences to be exchanged for one share of KBLM.
NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Sigma Labs (NASDAQ: SGLB), a leading developer of in-process, quality-assurance software for the commercial 3D-printing industry, has announced a new partnership with Northwestern University designed to develop its PrintRite3D(TM) In-Process Quality Assurance technology across an array of 3D printing processes. Sigma will work closely with its Northwestern University partner to expand the proprietary quality assurance technology and evaluate an application to powder-blow Directed Energy Deposition (“DED”) additive processes. Northwestern University acquired the first PrintRite3D DED system, and Sigma Labs developed the hardware and software for the system. The agreement calls for the installation of the beta system onto the customized open-architecture DED system, named Additive Rapid Prototyping Instrument (“ARPI”) system located at Northwestern’s Advanced Manufacturing Processes Laboratory (“AMPL”). Sigma Labs plans to seek additional commercial DED machine OEM partners to expand the beta testing program. DED has been applied in a variety of industries, including aerospace, oil and gas, defense, marine and architecture.” OEM’s have seen an increase in demand of the directed energy deposition machine ranging from high-level R&D projects to the production of prototype and production parts, many of which are for the aerospace industry,” said Sigma Labs CEO Mark Ruport in the press release. “This initiative expands our market opportunity and is the first step in Sigma’s strategy to apply our technology across a broad array of Additive Manufacturing processes.”
Sigma Labs is a leading provider of quality-assurance software to the commercial 3D-metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D-metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies in real time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Researchers from University of Queensland recently discovered that the droplets of fat that exist inside our cells help our body’s defense system fight back against infections.
The international collaboration between researchers Professor Albert Pol from the University of Barcelona and Professor Robert Parton from UQ Institute for Molecular Bioscience discovered these fat droplets to be both a weapon and a food source against bacterial invaders.
Professor Parton stated that scientists had previously thought the bacteria merely used the lipid droplets as food but had found out that the fatty droplets were also involved in the battle between our cells and pathogens.
He added that the fat is part of the cell’s armory. The cells fire these lipid droplets at these foreign pathogens once they manufacture toxic proteins and package them into the lipid droplets. This, he says, is a way that cells are using to defend themselves; they use fats as a weapon, which provides new insights into other ways to fight body infections.
This comes at a time when researchers are working hard towards finding alternative ways of fighting infections, as antibiotic-resistant superbugs are on the rise. One potential alternative would be to increase the body’s natural defenses.
Professor Pol stated that when white blood cells called macrophages were infected, they observed that the lipid droplets moved to the part of the macrophage that housed the bacteria.
They noted that how white blood cells used energy was also affected by the bacterial infection. Pol added that the lipid droplets could be used as an alternative source of fuel for mitochondria when other nutrients weren’t sufficient. During an infection, the lipid droplets moved away from the mitochondria and attacked the bacteria instead, which altered the cells’ metabolism.
Professor Parton, who is a cell biologist, was inspired to carry on with this research after the phenomenon that was observed in fruit flies.
He remarked that many had thought the lipid droplets to be blobs of fat which were only useful for energy storage. However, now that researchers have observed them acting as metabolic switches in the cell, defending the body against infection and more, entire scientific conferences of researchers have been dedicated to researching more about them.
He then added that the next step in their research was to discover how the lipid droplets targeted the bacteria. That way, they could not only understand the body’s natural defenses but also develop new therapies that would be reliant on antibiotics to fight infections that were drug-resistant.
The biomedical space is bringing to light lots of novel discoveries and therapies based on those discoveries. One interesting company to watch in this regard is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). They focus on developing products to address any unmet needs of treating different conditions yet clinical evidence of efficacy for helpful interventions exists.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
“Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention,” the Mordor Intelligence study stated. “The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment and lifestyle for each person, while developing drugs and vaccines.”
The report goes on to note that North America currently dominates the precision medicine market and is “expected to continue its stronghold for a few more years.” The United States holds the largest market share on the continent, at least in part due to the Precision Medicine Initiative (“PMI”), launched by former President Barack Obama.
This initiative was designed to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into everyday clinical practice. The PMI enjoys widespread support, including ongoing efforts through the Department of Veteran’s Affairs (“VA”), the Food and Drug Administration (“FDA”), the Office of the National Coordinator for Health IT and the Office for Civil Rights.
The study also reports that “precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. . . . The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.”
This analysis bodes well for Predictive Oncology, an industry leader focused on the use of data and artificial intelligence (“AI”) to develop predictive models of tumor drug response and outcome, which can be used to help oncologists individualize current cancer therapies for the patients as well as help researchers find new cancer therapies. The Mordor report noted that key factors propelling the growth of the precision medicine market include increasing online collaborative forums, increasing efforts to characterize genes and advancements in cancer biology — all of which POAI is involved in.
“The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type,” the report observed. “Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.”
One of POAI’s primary projects, conducted through its subsidiary Helomics, is building multi-omic predictive models of tumor drug response and outcome using a its unique proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from over 15 years of clinical testing. Using artificial intelligence, the company is leveraging this data to build predictive models of tumor drug response. These models offer researchers in pharma, biopharma and diagnostic companies actionable information that drives the development of new precision therapies, companion diagnostics, biomarkers and helps design better-targeted trials — all with the end goal of helping patients diagnosed with cancer.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated, patient-derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
A new study reveals that the lockdowns imposed in various countries to curb the spread of COVID-19 at the beginning of the pandemic around Europe and in China improved air quality. This was seen in regions that suffered from high mortality rates caused by air pollution.
Scientists from the University of Notre Dame recently published research in the Lancet Planetary Health journal that showed the decline in particulate matter concentrations in Europe and China. During the lockdown that was imposed in Europe between February 21 and May 17, particulate matter concentrations reduced by 17.1% while in China, the concentrations reduced by 29.7% in the lockdown period of February 1 and March 31.
These concentrations are small airborne particles that come from different combustion-related sources, such as wildfires, transportation, industrial emissions and chemical reactions of pollutants in the atmosphere.
The corresponding author of the study, Paola Crippa, says that the lockdowns, which have led to forced low-emission scenarios due to restrictions, show that very polluted areas can improve immensely in reducing air pollution if strict measures are put in place.
Air pollution may not sound as a real threat but is actually considered to be the leading environmental cause of death. So, it is in fact, a real and credible threat. The World Health Organization released findings in 2016 that showed the number of premature deaths caused by air pollution worldwide to be 4.2 million. The Southeast Asian and Western Pacific regions were the most affected by this.
Long-term exposure to areas with high air pollution can be fatal to humans and their health, with many succumbing to death due to lung cancer, chronic obstructive pulmonary diseases, stroke and ischemic heart disease.
The research team led by the author, who is also an assistant professor in the Department of Civil and Environmental Engineering and Earth Sciences at the University of Notre Dame, estimated that in China from February to March, about 24,200 deaths associated with particulate matter were prevented. They also noted that the improvement in air quality was recorded across China because of the lockdown measures that were imposed and extended. In Europe, the study estimates that 2,190 premature deaths were averted during the lockdown period.
This study highlights the need for stricter control policies to be developed and implemented in order to reduce air pollution and achieve effective air quality improvements. The policies may also include subsidies to electric vehicles as well as the adoption of strict emission limitations for industries.
Many biomed companies have set out to save thousands if not millions of lives. One interesting firm you should watch is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). They specialize in developing novel remedies for metastatic and primary cancers, especially those affecting the central nervous system and the brain.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, October 21st, 2020UncategorizedComments Off on $CNSP Coronavirus Lockdowns Forestalled Thousands of Air Pollution-Related Fatalities, New Study Finds
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstanis vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he is also the Austin Ricci chair in pediatric pulmonary care and research at University Hospitals Rainbow Babies and Children’s Hospital in Cleveland, Ohio. Konstan has spent his entire professional career in the care and research of people with cystic fibrosis (“CF”). Conwell is a gastroenterology physician-scientist specializing in pancreas disorders and is a professor of medicine at The Ohio State University College of Medicine where he serves as director of the Division of Gastroenterology, Hepatology and Nutrition at The Ohio State Wexner Medical Center. He is an NIH-funded physician-scientist with over 200 peer reviewed publications. The leader of numerous national and international studies of potentially new therapies in CF, Wilschanski is director of pediatric gastroenterology at Hadassah Hebrew University Medical Center. In addition, he also serves as the director of the Electrophysiology Laboratory in Hadassah where he performs in vivo and in vitro measurements of electrolyte transport, which is used diagnostically and therapeutically in CF. “We are thrilled to have this distinguished group of scientific leaders helping to guide our research and clinical development efforts as we advance our MS1819 program for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis patients,” said AzurRx CEO James Sapirstein in the press release.
AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, NY, with scientific operations based in Langlade, France, and clinical operations in Hayward, California. For more information about the company, visit www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Rritual is a private company and premium brand in the emerging functional mushrooms market. The company is dedicated to helping people meet the demands of modern life with style and ease by enriching their diets through incorporating functional mushrooms, adaptogens and superfoods. Rritual manufactures premium plant-based products, with each featuring mindfully selected ingredients and designed to fit every lifestyle and meet the demands of customers with various needs. A recent article discussing the company reads, “Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.”
Launched in 2019, Rritual makes premium, plant-based elixir products in small batches featuring mindfully selected medicinal mushrooms and adaptogenic herbs. To help support and achieve an optimal need-state, Rritual offers a range of products to fit every lifestyle. Rritual produces simple mushroom adaptogen products with limited, yet very purposeful and organic ingredients. For more information about the company, visit www.WeAreRritual.com.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Round of financing led by Bruce Linton, executive chairman of Gage Cannabis and cannabis industry pioneer
Reg A+ equity financing offers chance to invest in exclusive cultivator, processor, and retailer of world-leading cannabis brands
First step in Gage’s journey to becoming publicly traded company
Gage Cannabis Co., the leading high-quality craft cannabis brand and operator in Michigan, has launched a Regulation A, Tier 2, equity financing. The pre-IPO round of financing is being led by Bruce Linton, executive chairman of Gage Cannabis, a founder and former CEO and chairman of Canopy Growth Corp.
“We wanted to provide investors with the opportunity to invest in a growing and dominant cannabis operation before an official IPO process,” said Linton. “Michigan is one of the top cannabis markets in the U.S., and I am confident Gage is poised to continue building on its historical execution and fortifying its position as one of the top operators and brands in Michigan, as well as a name consumers look for across the United States.”
Linton transformed Canopy Growth Corp. from a concept into one of the most recognizable and valuable cannabis companies in the world. A passionate entrepreneur, he has decades of experience in a variety of industries, creating unprecedented long-term shareholder value. As the first and lead investor in the offering, his unwavering support and confidence in Gage Cannabis is clear.
The round of financing consists of up to 28,571,400 shares of subordinate voting shares, available for $1.75 per share. The shares are being offered pursuant to Regulation A of Section 3(b) of the Securities, as amended, for Tier 2 offerings, by management on a “best-efforts” basis directly to purchasers who satisfy the requirements set forth in Regulation A.
For investors, the pre-IPO opportunity to invest in the exclusive cultivator and retailer of several world-leading cannabis brands can’t be ignored. The company’s exclusive brands include Cookies, Lemonnade, Runtz, Grandiflora, SLANG Worldwide, and OG Raskal; Gage also has its own proprietary brand portfolio, distributed in Michigan.
The leaders at Gage Cannabis are focused on becoming the retailer of choice among adult-use and medical-cannabis consumers. Initially, Gage has opened five dispensaries, with plans to open three more locations by the end of 2020; the company intends to have more than 20 operating stores by the end of next year. So far this year, Gage has reported $31 million in sales, with that number only expected to increase in the coming months.
“We’re excited to invite public investors to join alongside industry juggernauts, like Bruce Linton, and provide them with the opportunity to participate in our future success,” said Fabian Monaco, President of Gage Cannabis. “We have strategically acquired a portfolio of high-quality operating assets and brands in the rapidly growing Michigan market and developed a reputation for providing consumers with access to craft cannabis in elevated retail environments. This is a great first step in our journey to becoming a publicly traded company, and we’re excited to continue to build on our strong foundation while delivering long-term shareholder value.”
Gage Cannabis Co. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).
The Company encourages all interested investors to visit GageInvestors.com for a link to the Offering Circular and to learn how to invest in the Offering. Financing information is also available by calling toll free at 1-844-606-0809 or locally at 1-616-504-6060
NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis Co. are available in the company’s newsroom at https://nnw.fm/GAGE
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Tuesday, October 20th, 2020UncategorizedComments Off on Gage Cannabis Co. Announces Pre-IPO Financing Round, Early Opportunity to Invest in Top Operator
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. (“Pii”), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for the drug; the two companies are located in different countries. CNSP contracted with Pii to make the drug in the United States and is working with BSP Pharmaceuticals S.p.A. (“BSP”) in Italy as well. BSP is on schedule to complete manufacturing later this year. CNS has also partnered with three separate companies as it prepares for its upcoming clinical trial of Berubicin. Worldwide Clinical Trials is the project’s contract research organization, Image Analysis Group (“IAG”) is the imaging partner and Berry Consultants will be the biostatistical advisor for the Phase 2 trial design. “Completing the manufacturing process for Berubicin in the United States is an essential step in our preparations to file an IND during the fourth quarter of this year,” CNS Pharmaceuticals CEO John Climaco stated in the press release. “We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner. We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Researchers at Brock and McMaster universities have developed a prototype for a tool which will allow patients to use a blood sample to test for the presence of cancer biomarkers. This technology has specifically been designed to assess the levels of prostate-specific antigens (“PSA”), but it can be tweaked to test for other cancers as well.
According to the researchers, the device operates in just the same way that hand-held glucose monitors work. A patient just mixes a tiny drop of blood in a vial which contains a reactive fluid, and then a sample from this mixture is placed on a strip which is inserted into the portable device for analysis.
In a couple of minutes, the reader would provide results showing the extent to which the cancer antigens are present in the blood sample tested.
Leyla Solemani, one of the lead researchers on this project based at McMaster’s University and also the chair of Miniaturized Biomedical Devices in Canada, stated that their work was a big step towards the delivery of personalized medical care to patients, in exactly the same way as what biomed companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are attempting to deliver customized medical care around the world.
The prototype takes diagnostics and monitoring away from hospital settings and brings it into the homes of patients. This makes cancer prognosis and diagnosis more accessible, especially for populations that aren’t close to the healthcare centers with the needed testing facilities.
The developers say that their device will need to undergo broader tests before the necessary regulatory approvals can be secured to pave the way for the commercial production and widespread use of the diagnostic tool.
However, the research team is optimistic that their device will pass all the regulatory requirements and it will be used to save lives and revolutionize clinical outcomes for the patients who are most in need of testing services.
The ability to gather real-time data about the progress of a cancer patient would help doctors and other allied professionals to design appropriate treatment protocols while making timely adjustments to those treatment plans as the condition of the patient evolves. This would be preferable to responding long after the condition of the patient has changed and the change is discovered when the patient comes to a health facility for their scheduled follow-up sessions. The era of lab-based tests could soon come to an end if such hand-held testing kits become widely available.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, continues to expand its U.S. footprint amid increased nationwide demand for environmentally sustainable waste solutions. SGTM recently entered a packaging agreement between its subsidiary Mulch Manufacturing Inc. and Old Castle Lawn & Garden to supply large home improvement chains in the Midwest. The agreement is one in a series of strategic moves in line with SGTM’s corporate strategy, which combines three pillars — operation expansion, strategic acquisitions and internal investment. These moves have enabled the company to expand and profit at a time of global economic contraction. “I am honored to have been engaged by Old Castle Lawn & Garden and to secure a packaging agreement with this global company, increasing our strategic partnerships,” said SGTM CEO and Director Tony Raynor in recent statements (https://nnw.fm/Xt66J).
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris, which has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting tree debris through its tree services division and collection sites and then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic-growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients.
For additional information regarding SGTM’s operations, expansion plans and production facilities, view the company’s presentation. For more information about the company’s Mulch Manufacturing subsidiary, visit www.MulchMfg.com.
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
SRAX (NASDAQ: SRAX), an innovative fintech solutions provider, together with BIGtoken(R) Inc., a company started as a division of SRAX, today announced the addition of Daina Middleton and Yin Woon Rani to its board of directors. With these two new appointments, Middleton and Rani will join SRAX CEO Christopher Miglino and BIGtoken CEO Malcolm CasSelle on the board for BIGtoken. “We are very pleased to have Daina and Yin join our board,” CasSelle said in the news release. “Daina’s marketing and leadership experience with large corporations like Twitter and HP combined with Yin’s extensive CPG background, having worked at Campbell Soup and the Grey Group agency where she managed accounts with Hasbro, P&G and M&M, will make the leadership team here at BIGtoken a true powerhouse. BIGtoken is ready to take on the next phase of growth and, with our two new board members, we are sure to make a substantial impact in the digital media and data space.”
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
A study led by researchers at the University of Texas Southwestern Medical Center suggests that native chemicals (endocannabinoids), which are similar to the cannabinoids produced by marijuana plants, have the potential to inhibit the virulence of intestinal bacteria.
The team found that our endocannabinoids can shut down the genes which are required for some intestinal pathogens to colonize and cause disease. This study sheds some light on why marijuana has for long been used to alleviate different gastrointestinal infections.
The researchers sought to establish whether endocannabinoids can lessen one’s susceptibility to the different pathogenic bacteria which cause gastrointestinal infections.
To answer this question, the team genetically altered a group of mice so that the rodents could produce higher levels of an endocannabinoid called 2-AG (2-arachidonoyl-glycerol). The genetically modified mice were then injected with a bacterial pathogen called citrobacter rodentium. This pathogen is responsible for attacking the colon and causing extreme inflammation and diarrhea. Unmodified mice were also injected with this pathogen.
The researchers then observed that the unmodified mice displayed severe gastrointestinal distress characterized by colon inflammation, severe diarrhea and signs of infection. Their fecal matter also had high levels of citrobacter rodentium.
However, the genetically modified mice not only recovered days quicker than their unmodified cohorts, but they also had lower inflammation markers in their colons, and their symptoms of infection were mild.
The researchers then genetically modified the mice which hadn’t initially mutated and when these were injected with the pathogens, they exhibited mild symptoms and recovered quickly from the infection.
Vanessa Sperandio, PhD, the leader of this study, revealed that the endocannabinoid 2-AG also protected the mice from E-coli and salmonella typhimurium.
When the team treated mammalian cells in a petri dish with a compound which blocks 2-AG, those cells had a heightened susceptibility to the gastrointestinal pathogens with which the mice had been injected.
The research authors observe that their findings could explain why cannabis compounds or their synthetic versions have beneficial effects on inflammatory bowel issues. They believe that with such findings, it could soon be possible to use the body’s own compounds or those derived from plants to treat infections in a way that hasn’t been attempted before.
It is noteworthy that this research was supported by five grants from the National Institutes for Health (“NIH”). These findings will undoubtedly open the door of possibilities to lots of biomedical companies. One biomedical company whose work is worthy looking into is Predictive Oncology (NASDAQ: POAI). They focus on delivering precision or personalized cancer medicine using the power of artificial intelligence and data.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Despite the concept of electric vehicles (“EVs”) being decades old, the industry is relatively new. Consumers interested in reducing their carbon footprint and switching green are positively bursting with questions about the fledgling industry and how it works. To help interested parties get a clearer picture of the EV industry, consumer group Which? Has given expert answers to five of the most nagging EV questions most consumers have.
Are electric cars really that green? You’d be forgiven for thinking EVs produce zero emissions, but we’re still a ways off from that technology. But don’t let that discourage you from going green: research has found that although electric cars are not entirely green, they don’t pollute the environment as much as petrol and diesel-powered vehicles. According to an analysis by BloombergNEF, carbon emissions produced by electric vehicles charged with non-renewable power are still 40% lower than the outputs of cars with combustion engines.
How much do I have to worry about range? Not as much, apparently. While drivers who went green early had to fork over a lot more for an expensive EV with more range, improvements in battery technology have resulted in much more affordable models with extended ranges. Instead of paying a whopping $103,000 on an expensive Tesla so you can travel more than 200 miles on a single charge, you could opt for more affordable models like the Hyundai Kona or the Kia e-Niro that will offer you similar range.
Are electric cars more reliable? Compared to traditional vehicles, electric vehicles have far fewer moving parts, and the assumption is that this makes them more reliable and less likely to break down. However, a 2019 poll found that petrol and hybrid car owners had fewer problems to report than EV owners. Just over one in four owners of EVs under three years old reported an issue. But despite the higher overall fault rate, EV owners are still among the most satisfied car owners.
Are electric cars more practical to run? If you have a home charger and are confident you can charge your EV somewhere off the road, then yes, it would be practical to own an EV. However, if you live in flats or have to rely on the famously unreliable public charging systems, you may find yourself questioning the choice to go green. Unless you drive a Tesla, which has its own charging network, and you cannot install a home charger, you may have to rely on several apps, websites, or a radio-frequency identification (“RFID”) card to gain access to public charging networks.
Are EVs less expensive to own than traditional vehicles? Overall, studies have shown that EVs are cheaper to own and maintain over their lifetime than petrol and diesel-powered vehicles. However, as the initial costs can be quite high, plenty of prospective buyers are unable to go green. Improvements in battery technology over the next five years will make EVs much more affordable but at the moment, customers have to rely on government programs and grants that make buying relatively expensive EVs possible.
Several companies are picking interest in the electric vehicle space with the view to addressing some of the little kinks that still exist in this vehicle segment. One such company that is interesting to follow is Net Element (NASDAQ: NETE). The global financial solutions company is set to complete a reverse merger with an electric vehicle maker.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
If you are planning to buy some mining industry stocks, it is wise to do your due diligence so that you don’t fall for clever marketing hype geared at luring unsuspecting investors into pouring money into a risky company. Here are some specific issues to investigate with respect to a company’s mineral exploration activities.
Geological Potential
A mining company needs to base its exploration activities on sound science rather than on speculation. It is therefore vital for you to confirm that the company you wish to invest in invests in exploration and can provide proof of geological indicators for the prospects that they are pursuing. If the jurisdictions in which they are exploring show geological potential, put a check on that specific box and evaluate the other issues on your checklist.
The Legal Environment
With competent management and proper laws, a mining company’s exploration activities can yield the expected results while the same cannot be said for a jurisdiction with unclear or inconsistently implemented laws.
An appropriate legal framework is like a well-paved highway. As you select which mining stocks to buy, find a company whose operations are based in jurisdictions with well-laid permitting processes, a history of laws that support mining activity and relatively low bureaucratic requirements.
The Political Environment
In some jurisdictions, policies can suddenly and drastically change based on who wins an election. For example, when a leader who is against mining gets elected as president, he or she can quickly nationalize all mining operations to the detriment of the affected mining companies.
It is therefore wise to sieve out those mining companies which don’t operate in jurisdictions where there is rule of law and government policies are stable. Otherwise, buying stocks in a company operating in jurisdictions rife with corruption or where the political system is volatile means you are taking on way too much risk.
Infrastructure and Labor
It is desirable that mining exploration takes place in an environment which has suitable infrastructure, such as gridlines, road networks and trained labor to execute the exploration activities. If such infrastructure is lacking, a forward-looking mine can make plans to be the catalyst that spurs development in the jurisdictions where it operates. This can be a great way to win the support of the local communities.
When you identify a mining company whose activities check all the boxes above, you will have moved a step closer to ensuring that your money is safe and that you will get a return on your investment. A company of interest that you can look at while studying the factors above in operation is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). They specialize in the production of uranium and vanadium, both of which are categorized by the U.S. federal government as critical minerals.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Researchers seem to have discovered a new way to manage diabetes without using needles or any other invasive means. The University of Iowa team found that when diabetic mice were exposed to a combination of magnetic fields and static electricity fields for a few hours on a daily basis, it caused them to have normal insulin and blood sugar levels. This unexpected discovery opens the door to a novel way of managing diabetes in humans more easily and safely.
According to the findings which appeared in the journal Cell Metabolism on October 6, the initial discovery which led to this research was purely accidental. Sunny Huang, one of the researchers on this study, needed to practice how to draw blood from mice and measure the blood glucose levels of the samples taken. Calvin Carter, PhD, the co-lead author, give Sunny several rodents which he had been doing research on regarding how electromagnetic fields affect the behavior and brains of mice.
Sunny was astounded to find that all the mice had normal blood glucose and insulin levels and yet mice exposed to EMF tended to have high blood pressure and diabetes. What was more shocking was the fact that these particular mice had been genetically modified so that they could all be diabetic.
When Carter’s attention was drawn to this anomaly, a partnership was born to study how EMFs could be used to treat or even reverse diabetics. The researchers felt that if they investigated the matter further and confirmed that electromagnetic fields and static electricity could indeed reverse the biomarkers for diabetes, then a major way to handle diabetic patients would have been opened. The results held up.
The researchers say that there are indicators everywhere that some cells in the body are uniquely designed to respond to electromagnetic radiation. For example, migratory birds are said to rely on EMFs for navigation.
The team found that an oxidant molecule called superoxide in the liver of mice was responsible for the activation of an antioxidant body response which rebalanced the body’s ability to react to insulin and control blood sugar levels.
When the researchers removed those superoxide molecules from the liver, they noticed that EMFs couldn’t have any effect on the insulin and blood glucose levels of the mice.
The team is now turning its attention to studying whether the beneficial effects of EMFs on diabetes can also be replicated in humans. If that turns out to be the case, the researchers hope to develop therapies around their discovery. There are lots of biomedical companies out there striving day and night to come up with new ways to address the current health challenges. One interesting company which you can watch is DarioHealth Corp. (NASDAQ: DRIO). They focus on digital therapeutics and they have popularized smartphone-based software to manage chronic illnesses.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.”
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced its entry into agreements with six kindergartens in Xiamen to conduct “Augmented Reality Immersive Classes” (“ARIC”) for students. Xiamen, where Blue Hat is headquartered, has a population base of approximately 3.5 million. The company hopes to engage with over 50 kindergartens by the end of 2020. “We are so delighted to deploy our ARIC immersive software classes in six kindergartens in Xiamen,” BHAT CEO Xiaodong Chen said in the news release. “For several years, we have felt that the end applications of our AR interactive games and products can be utilized for both entertainment and educational purposes through the implementation of visual learning. In the future, the company will work with each cooperated kindergarten and work to improve and optimize our content for teaching purposes.”
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games and toys with mobile-game features. The company’s entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the company’s investor relations website at www.IR.BlueHatGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://nnw.fm/BHAT
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cannabis legalization activists in Vermont can finally breathe a sigh of relief after the governor announced that he will allow legal marijuana sales to take place in the state without his signature. Although the state legalized personal possession of up to one ounce and cultivation of two plants in 2018, retail sales have been prohibited. Governor Phil Scott’s decision to allow legal sales will finally create a tax-and-regulate system for the industry. On top of that, he also signed separate legislation to automate expungements for prior cannabis convictions.
Before being reconciled in a bicameral conference committee last month, different versions of the marijuana sales proposal passed each chamber. After the finalized proposal was sent by the legislature to the governor, he was non-committal about his plans for the legislation up to the day before the signature deadline. Although he hinted that he was considering vetoing the bill, he ultimately decided to let the legislation pass.
Most of Gov. Scott’s issues with the proposal had to do with impaired driving, taxes, and local control. Before the finalized proposal was presented to him, the governor stated that while he appreciated the legislative process the bill had gone through, certain racial justice groups had raised concerns with his office about how the proposal addressed social equity in the cannabis industry for communities that had been most affected by prohibition.
Last Tuesday, he stated that lawmakers “did move forward in a lot of areas that I had concerns about, but it isn’t exactly what I’d like to see and there are some shortcomings.” But when the time came, he stood out of the way and let the legislation pass. “However, there is still more work to be done to ensure the health and safety of our kids and the safety of our roadways – we should heed the public health and safety lessons of tobacco,” Gov. Scott wrote in a letter to lawmakers announcing his decision.
“Further, I believe we are at a pivotal moment in our nation’s history which requires us to address systemic racism in our governmental institutions. We must take additional steps to ensure equity is a fundamental principle in a new market. The concerns with this bill of the communities historically most affected by cannabis enforcement were not meaningfully incorporated into this bill,” he says.
He argued that lawmakers should consider creating a social equity applicant category for cannabis licenses as well as a 50% licensing waiver for those applicants and additional technical and financial assistance. Despite the bill’s apparent shortcomings, it has been celebrated by cannabis reform activists.
“It’s a great relief to learn that Vermont will finally move forward with plans to replace prohibition with sensible regulation,” says Matt Simon, New England Political Director for the Marijuana Policy Project. “Legislators bent over backward to address Gov. Scott’s concerns throughout this process, and it’s now clear that these difficult compromises weren’t made in vain.”
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
Friday, October 16th, 2020UncategorizedComments Off on $WTER 420 with CNW – Vermont Governor Allows Marijuana Bill to be Operational Without His Signature
Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announced that its wholly owned subsidiary, Mulch Manufacturing Inc., was awarded a one-year natural mulch supply contract with two additional one-year extensions with the city of Vero Beach, Florida. According to the update, the company secured the contract shortly after its receipt of a mulch contract from Circle K convenience store divisions. “We are pleased to be awarded this new government contract opportunity and it’s all thanks to our recently completed construction in the Waste Management facility in central Florida,” SGTM’s CEO and Director Tony Raynor said in the news release.
Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://nnw.fm/3iVHn
NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
SRAX (NASDAQ: SRAX), an innovative fintech solutions provider, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Christopher Miglino, founder and CEO of SRAX, and Chris Lahiji, president of LD Micro. During the program, the two executives discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced closing of the acquisition on Sept. 16, 2020, noting that LD Micro will operate as a wholly owned subsidiary of SRAX and will continue to employ Lahiji, its founder, as its president. “If you look at what we’ve built at LD, we’ve had a lot of interest over the last 11 or 12 years in getting acquired, but the reality was that every single organization wanted to use the community that we had built for the wrong purposes,” Lahiji stated in the interview. “Christopher Miglino was the only guy who came to me and essentially asked the right questions and found a way of taking what we had built since 2002 and enhancing it. . . . With SRAX, I have the ability to increase my reach by more than 100-fold without having to sacrifice anything that has been built prior to [the acquisition]. The dynamics that they bring to the table for LD are incalculable.”
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Sigma Labs (NASDAQ: SGLB), a leading developer of in-process, quality-assurance software for the commercial 3D-printing industry, has scheduled a conference call to discuss its third-quarter 2020 results. The call is scheduled for Thursday, Oct. 22, 2020, at 4:30 p.m. ET. The call will be hosted by Sigma Labs president and CEO Mark Ruport and CFO Frank Orzechowski, and will include an overview of the company’s performance covering the period ending Sept. 30, 2020. The two company executives will also participate in a Q&A session during the call. Those interested in accessing the call can dial in five to ten minutes prior to the call starting to register with an operator. Numbers are 1-877-407-9039 (toll free) in the United States or 1-201-689-8470 internationally; the conference ID for the call is 13711743. Those interested may also watch the broadcast live at https://nnw.fm/v7mJG or via the investor relations section of the company’s website at www.sigmalabsinc.com. In addition, the conference call will be available for replay through Nov. 5, 2020.
Sigma Labs is a leading provider of quality-assurance software to the commercial 3D-metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D-metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies in real time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
A lot can be said about what should or shouldn’t have been done to stem the spread of the novel coronavirus across the U.S. at the beginning of this year, but the truth is that the U.S. has unique factors that have influenced the trajectory of this pandemic. We analyze some of those crucial driving factors.
A Large Population
The U.S. is undeniably the third most populous country in the world, and that huge population provides a large sample space for the virus to get willing or unwilling hosts. When global COVID-19 cases are analyzed, the most affected countries also double as those with the largest populations. For example, the U.S., Russia, India, Brazil and Mexico. China doesn’t qualify for inclusion here because its caseload statistics are questionable at best.
To illustrate this population factor even more, a look at the most affected U.S. states indicates that they are also the ones with the largest populations in the country. These include New York State, California, Texas, Florida and Illinois.
Country Size
The novel coronavirus disease can generally be described as a regional disease, with larger countries finding it harder to contain outbreaks since they can spring up from anywhere across the vast stretch of the country.
Globally, the U.S. is the fourth largest country in terms of land mass. It therefore isn’t surprising that the U.S. has been badly affected by this pandemic since a look at the other worst affected countries shows that they happen to command a large land mass as well. They include Brazil, India, Argentina and Russia.
Mobility Within and Out of the Country
It is a known fact that the coronavirus doesn’t move from one place to another on its own. Rather, it is spread by people who travel from one location to another. According to several sources, such as the Washington Post, the U.S. takes the first spot in terms of internal travel by its residents. It also ranks as the third in terms of receiving travelers from other parts of the world, and it follows closely behind Spain and France. France and Spain have also taken a severe beating from the virus, and so did other countries like Italy which receive a lot of foreign travelers.
Diversity of the Population
Pew Research suggests that there is a genetic factor to the spread (or lack thereof) of the COVID-19 pandemic, and estimates indicate that the U.S ranks high among countries with diverse populations.
Diversity means that some sections of the population will exhibit degrees of resistance to the virus, while others will be highly susceptible to the infection. Other socioeconomic factors can also come into play, and that could be why predominantly black communities in the U.S. had it rough, just as the elderly in nursing homes.
It may be a little unfair to say the U.S. has been disproportionately affected by the pandemic because it is hard to adjust for the factors above in each country across the world for a fair comparison. Biomedical industry watchers wonder what entities like Processa Pharmaceuticals Inc. (NASDAQ: PCSA) would suggest to avoid such a catastrophe in future.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
It is hard to believe that the medical supply shortages which manifested a few weeks into the COVID-19 pandemic persist and have gotten worse in some cases. Ventilators, PPE and testing reagents are just a few of the critically needed medical supplies that the U.S. appears to be unable to get hold of in sufficient quantities. But why is this so?
In 2004, the administration of the day created the Strategic National Stockpile (“SNS”) with the aim of having a safety net during short-term emergencies, such as terrorist attacks. While this entity wasn’t designed or even equipped to handle an emergency of the scale of this current pandemic, they nevertheless should have been in position to alleviate some of these existing challenges. But they didn’t or haven’t. A number of glaring inadequacies could explain why the SNS hasn’t been of much help during this crisis.
Limited Clout and Visibility
Over the years, the sense of urgency that prompted the creation of the SNS has dwindled and subsequent administrations have allowed the agency to slide downwards on the list of critically needed teams.
For example, funding for restocking vital supplies has been cut almost every fiscal year, and this has left the SNS with no muscle to act when it deems fit.
Furthermore, the lack of clout has meant that even if the SNS raises an alarm about a situation, their voices aren’t given the attention they deserve. A clear example are the repeated warnings of SNS experts about the risks of globally significant diseases which have been ignored, and the strategic plan of SNS hasn’t been renewed since 2017.
More clout and greater visibility would have enabled this team to prevent some of the more severe effects of the medical supply shortages since their experts talked about these shortages from way back in January.
Inadequate Information Systems
A lot can be said about the inadequacy of the SNS’s information systems, but two examples will suffice. First, its data management system hasn’t been upgraded from 2004 from the time the agency was created. With the speed at which technology is changing, a 2004 information management system is obsolete!
The second example is that SNS staff have been seen using their smartphones to take pictures as evidence of supplies that they have received or dispatched. You can’t track critical supplies using just a photo, and it is therefore not surprising that badly needed medical supplies are in short supply across the country.
In short, the agency cannot “see” where supplies exist and where they are running out, so they can’t play their strategic supplies management role.
Crucial Expertise is Lacking
The job of tracking strategically needed medical supplies isn’t one that can be given to any person. Special expertise is needed. For example, the SNS lacks analysts to track the different supply chains of supplies that are deemed critical. If such an expert existed, the agency would have known that Wuhan, China is the major source of PPE and since it was the epicenter of the coronavirus outbreak, the world couldn’t expect to source its PPE from such a location. Alternative sourcing would have been quickly mobilized to save the U.S. from the shortages it has seen during this crisis.
Americans and biomedical entities like Predictive Oncology (NASDAQ: POAI) are left with a question: what is the way forward? Experts advise the federal government to look at the Department of Defense’s diverse teams that work under an apex leadership team to brief all related departments about any developments being tracked. If the SNS is given the clout and support it deserves together with the needed organizational restructuring, any future pandemic isn’t likely to hit the U.S. as badly as the COVID-19 crisis has.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Net Element (NASDAQ: NETE) has recently transformed its business model to become a pure-play electric vehicle (“EV”) manufacturer through its merger with privately-held Mullen Technologies Inc. The company is set to begin marketing its initial vehicle model – the Dragonfly K50 – in 2Q2021. Developed in conjunction with China’s Qiantu Motors, the car model will mark Net Element’s initial foray into the North American electric vehicle market. The venture will be further reinforced through the launch of the Mullen MX-5, the company’s self-manufactured EV SUV, by the second quarter of 2022. An article discussing opportune timing of the move reads, “In an extensive report centered around the battery electric vehicles segment, Deloitte recently forecast that the electric vehicle market is set to reach a tipping point in 2022 . . . a point of time at which the consultancy expects the cost of ownership for a battery-powered vehicle to be on par with its internal combustion engine-powered counterparts, thereby reducing relative cost differences as a barrier to purchase. With that in mind, it is noteworthy to explore the potential target market size for Net Element as it makes its initial foray into the global EV marketplace (https://ibn.fm/yTFRm).”
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017 Net Element was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Rritual Mushrooms Inc. is an emerging producer of premium plant-based superfood products designed to help people meet the demands of modern life with style and ease
The company introduced the wellness and nutraceuticals market to its suite of three mushroom and adaptogen-based elixir powders in September
Rritual Mushrooms’ products were created to boost immunity, support brain function and help the body fight anxiety
Rritual is positioned to take advantage of lifestyle trends that have promoted plant-based proteins and reduced meat consumption in recent years, as well as an invigorated interest in immunity-enhancing substances brought on by the worldwide COVID-19 pandemic
Modern lifestyle natural wellness innovator Rritual Mushrooms is growing into a wellness wonder at the heart of a fledgling industry rife with opportunity.
Market analysts at Grand View Research, Inc. reported last year that the overall functional foods market size is projected to reach $275.77 billion by 2025, expanding at a CAGR of 7.9 percent between 2019 and 2025 (https://nnw.fm/NO6n2). The demand for nutraceuticals and functional foods is now expected to surge even more than anticipated last year, in part as a response to consumers’ efforts to incorporate more immunity-boosting supplements into their diets as a result of the COVID-19 pandemic, building on an already extant decline in the consumption of meat products as plant-based proteins have gained favor, according to the report.
Functional mushrooms as a segment of that marketplace is new enough that there is no dominant brand in place to lead the category. Rritual Mushrooms has completed development of a suite of premium functional mushroom and adaptogenic elixir powders that were developed by a leading team of scientists, doctors and experts across the wellness industry. The company is exploring an opportunity with an IPO as well.
The initial product line of non-psychoactive wellness elixirs includes a Chaga blend designed to boost immunity, a Lion’s Mane blend designed to support cognitive function and brain health, and a Reishi blend to help the body fight anxiety.
Chaga is found most commonly in birch forests of the Northern Hemisphere (https://nnw.fm/2MBDO) and Rritual’s blend pairs it with the adaptogen Eleuthero root (https://nnw.fm/wtc4L) for a product full of bioactive polysaccharides. Adaptogens are natural substances used in herbal remedies because they are thought to increase the resistance of organisms to biological stress (https://nnw.fm/0DCkY).
The Lion’s Mane mushroom is native to North America, Europe and Asia (https://nnw.fm/qMxa6) and Rritual’s blend pairs it with the adaptogen Rhodiola root (https://nnw.fm/5QtuG). The Reishi mushroom is used in traditional Chinese medicine and has been referred to for thousands of years as the mushroom of immortality (https://nnw.fm/qx70X). Rritual infuses it with the adaptogen Ashwagandha root (https://nnw.fm/c14go) for a combination rich in polysaccharides, triterpenes, amino acids and fatty acids that may improve quality of sleep for restless minds.
“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Rritual President Dr. Mike Hart stated in a September news release announcing the new elixir powder product lines (https://nnw.fm/9UBDg).
The three formulations will be available in 14-stick packs and in 150-gram containers during the fall, and there will also be a 14-day variety pack that includes all three elixirs. They will be marketed through Rritual’s website and the company’s Amazon store initially, but the company expects to add outlets by building on its team connections with specialty e-commerce channels such as Costco, CVS, Walmart and Vitacost.
The company similarly anticipates building to a brick-and-mortar rollout of its products through team connections with retail outlets such as Wegmans, Fresh Thyme, Whole Foods, Shaw’s, Stop & Shop, Vitamin Shoppe, Target and Kroger submarket Ralphs and Harris Teeter stores.
NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China
180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. IV, with the resulting entity to list on NASDAQ under the ticker “ATNF”
The company is devoting its clinical-stage biotechnology research to producing solutions that will help battle inflammation. Its primary focus is to treat fibrosis and inflammation using anti-TNF therapy
The estimated annual market size for anti-inflammatory therapeutics is projected to grow to an estimated $106.1 billion in 2020.
KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that has signed a detailed merger agreement with 180 Life Sciences Corp., announced that the company has continued to expand its IP portfolio. 180 Life Sciences Corp. is a clinical-stage biotech company currently in the developmental stage of three novel drugs. These drugs will fulfill the unmet need within the healthcare industry for inflammatory diseases, pain, and fibrosis.
The current patent portfolio that 180 Life Sciences Corp. has applied and received licenses for covers 14 patent families consisting of 42 patents issued and 32 pending in jurisdictions such as the United States, Europe, Canada, Japan, Australia, and China (https://nnw.fm/AMNwy).
The latest patent, granted on June 3 by the EU Patent and Trademark Office, is for methods of prevention or treatment of triggered inflammatory reactions using TNF alpha antagonist. “The issuance of our European patents significantly strengthens the IP portfolio governing our lead program,” 180 Life Sciences Corp. CEO Dr. James Woody said in the IP portfolio announcement.
“We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies,” Woody added. “Having this most recent patent awarded in the EU is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization, and partnering efforts throughout Europe. We look forward to achieving additional milestones by the end of 2020.”
On June 2, the company was granted a U.S. patent for the treatment of Dupuytren’s Disease, while on January 14, China granted a patent for synthetic CBD analog (“SCA”): cyclohexenyl compounds, compositions comprising them and uses. In addition, the company filed a patent for SCA bioactive phenolate ionic complexes in the U.S. on April 22 and one for method treating systemic fibrosis disorders using IL-33/TNF specific antibody, in Hong Kong on September 1.
The company’s patent portfolio comprises its own IP and exclusive worldwide licenses, including the Hebrew University, The Kennedy Trust for Rheumatology Research University of Oxford, Oxford University Innovation Limited, and Stanford University.
180 Life Sciences is currently conducting three clinical programs to address the following indications:
A Phase 2b/3 trial on Dupuytren’s contracture, a fibroid disease of the hand, with expected results in Q1 2021
A clinical study to be initiated for frozen shoulder with a grant awarded by the National Institute of Health Research, UK
A current unmet need in the elderly population, especially those who undergo hip replacement – post-operative cognitive delirium disorder and dysfunction
In addition to the current clinical trials, 180 Life Sciences Corp. currently has preclinical discoveries focusing on developing unique, FDA-approved pharmaceutical-grade cannabinoids for arthritis treatment. It is also working with an a7nAChR program initially aimed at the treatment of ulcerative colitis after smoking cessation (https://nnw.fm/nPn2g).
These studies, along with its expanding IP portfolio, are helping the company position itself as a leader on the anti-inflammatory therapeutics market, which is expected to grow to an estimated $106.1 billion in 2020. The company’s merger with KBL Merger Corp. IV is also expected to strengthen its position, while also enabling it to go public.
An October 12, 2020 announcement by KBL Merger Corp. IV indicated that the Form S-4 that was filed with the SEC regarding the merger is now effective. The company has scheduled a Special Meeting of the Shareholders for October 26, 2020. Once the merger is complete, 180 Life Sciences Corp. will list on NASDAQ under the ticker symbol “ATFN.”
NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Related Editorial
Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies. Several clinical trials are underway in the United States and worldwide to investigate the therapeutic effects of psilocybin, the active component in the fungi known colloquially as “magic mushrooms.” There is new hope for treating such debilitating disorders as depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addiction. With more than $6.8 billion on the line by 2027, companies at the vanguard of the psychedelic therapeutic drug market could reap enormous benefits in the coming years. Some of these companies, such as Cybin Corp. (Cybin Profile), which focuses on drug development and unique delivery mechanisms, are targeting areas that have been particularly underserved in the past decade. Those areas encompass life-disrupting psychiatric and neurological conditions such as major depressive disorder (MDD), addictions, and other mental illnesses. A pioneer in the psychedelic sector, CYBIN is working toward becoming the first life sciences company to bring a psilocybin drug targeting MDD to market. A successful outcome could completely upend treatment protocols. The psychedelic space’s promise is perhaps best illustrated by the sector’s largest-ever private financing round of $80 million for Compass Pathways (NASDAQ: CMPS), the first psychedelic company to IPO on the NASDAQ. Not to be outdone, Mind Medicine Inc. (OTC: MMEDF) is following suit; the company applied for NASDAQ uplisting last month. In addition, Field Trip Health Ltd. (CSE: FTRP) started trading on the Canadian Securities Exchange (CSE) earlier this month.
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced that it will hold a live Zoom video webcast to discuss its financial and operational results for the third quarter ended September 30, 2020. Results will be issued in a press release prior to the event. The webcast is set to take place at 4:30 p.m. Eastern Time on Thursday, October 29, 2020. Wrap Technologies’ management will host the live video webcast, followed by a question and answer period, which will be linked from Wrap’s investor relations website. Interested parties may register for the event at https://nnw.fm/7NQqa.
Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, LaGrange, St. Cloud and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.
NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://nnw.fm/WRTC
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
